Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07526675 | Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer(Bioblation) | recruiting | N/A | 30 | Benha UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07550478 | Impact of Pharmacist-Led Intervention on Adult Oncology Outpatients | completed | N/A | 81 | Badr UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)(ABCD RT) |
| not yet recruiting |
| Phase 3 |
| 5,270 |
| NRG OncologyOTHER |
| 0 |
| Sep 30, 2026 |
| clinicaltrials |
| NCT07570056 | Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance) | not yet recruiting | — | 25 | University of UtahOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07599007 | Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion | not yet recruiting | — | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07621471 | IL-15 Enhanced NK Cell Therapy for Solid Tumors | recruiting | Early Phase 1 | 12 | Genovn Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07634536 | Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant | not yet recruiting | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer(TARGET-D 202) | recruiting | Phase 2 | 105 | Verastem, Inc.INDUSTRY | 3 | Sep 30, 2026 | clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07695415 | Network-Guided Theta Burst Stimulation for Breast Cancer With Chemotherapy-Induced Peripheral Neuropathy: Clinical and fMRI Biomarker Evidence(CIPN TBS) | not yet recruiting | N/A | 40 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07698314 | A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer(Myo-EXERTBC) | recruiting | N/A | 21 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | not yet recruiting | Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma(RAZOR) | not yet recruiting | Phase 3 | 140 | Australasian Leukaemia and Lymphoma GroupOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | recruiting | Phase 2 | 55 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07744152 | A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 137 | Boehringer IngelheimINDUSTRY | 5 | Sep 30, 2026 | clinicaltrials |
| NCT07782814 | An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool(DiTECT) | recruiting | — | 220 | Zedsen LimitedINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07829068 | Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy(INTROSPECT) | active not recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07835412 | A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways | recruiting | — | 5,000 | Beijing Tiantan HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | Liping DouOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07842835 | Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China(CLIMB) | recruiting | — | 400 | Xiaohui RenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 30, 2026 | clinicaltrials |
| NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | not yet recruiting | Phase 1 | 112 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 7 | Sep 30, 2026 | clinicaltrials |
| NCT07848360 | Traction-Assisted Versus Conventional Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors(TRACE-NET) | not yet recruiting | N/A | 66 | Pusan National University HospitalOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848568 | Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Children's Oncology GroupNETWORK | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | recruiting | — | 40 | Beijing Municipal Administration of HospitalsOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848815 | Risk-Based Lung Cancer Detection in COPD Patients(ELUCID) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848828 | Autonomic and Renal Contributions to Hypertension With ADT(ARCH) | recruiting | Phase 4 | 50 | Virginia Commonwealth UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848841 | Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery | recruiting | N/A | 50 | Washington University School of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | recruiting | Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849218 | A Study of DXC018 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849231 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms(CLARITY-101) | recruiting | Phase 1 | 250 | Damora TherapeuticsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849400 | Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery | not yet recruiting | N/A | 566 | Diansan SuOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849543 | Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study | not yet recruiting | N/A | 190 | Thomas Jefferson UniversityOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07849608 | Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer | recruiting | — | 200 | Qun ZhaoOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849660 | Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | active not recruiting | — | 170 | Eisai Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849712 | An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer(BEACON-OLD) | not yet recruiting | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850284 | SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850336 | Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment(PERFECT) | not yet recruiting | N/A | 56 | Bojan KovacevicOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07850453 | Vortosiran for VTE Prevention | not yet recruiting | Phase 2 | 150 | Ribocure Pharmaceuticals ABINDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT07850778 | ONS USE IN COLON CANCER(ONS COLON CA) | completed | — | 209 | Osmaniye Korkut Ata UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850791 | A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer | recruiting | Phase 2 | 38 | Haitao Zhao, MDOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | not yet recruiting | Phase 1 / Phase 2 | 192 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 30, 2026 | clinicaltrials |
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT00027326 | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
Data updated yesterdaySource updated Sep 30, 2026source: clinicaltrials